Haviland Kate 4

What Happened
Kate Haviland, a director of Fulcrum Therapeutics (FULC), was granted a derivative award covering 32,000 shares on June 30, 2026. The Form 4 reports the acquisition price as $0.00 (no cash paid at grant). This is a compensation grant (award/option-style derivative), not an open-market purchase or sale.

Key Details

• Transaction date: June 30, 2026; Form 4 filed July 2, 2026.
• Amount: 32,000 shares reported as a derivative acquisition; reported price $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The award "is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service."
• Filing status: Form 4 filed following the grant (no late-filing note in the provided data).

Context
This was a grant of a derivative/option-style award as part of director compensation. Such grants typically vest over time and require satisfaction of vesting conditions (and sometimes exercise) before converting to tradable shares, so they are different from outright purchases or sales and do not by themselves signal an immediate buy or sell by the insider.